Tolvaptan (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Tolvaptan" in Italian language version.

refsWebsite

Global rank Italian rank

799^th place

22^nd place

2^nd place

7^th place

4^th place

9^th place

68^th place

57^th place

1medicalnewstoday.com

3,011^th place

4,667^th place

2,374^th place

1,283^rd place

447^th place

644^th place

doi.org

dx.doi.org

Shoaf S, Elizari M, Wang Z, etal, Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias, in J Cardiovasc Pharmacol Ther, vol. 10, n. 3, 2005, pp. 165–71, DOI:10.1177/107424840501000304, PMID 16211205.
Gheorghiade M, Gattis W, O'Connor C, etal, Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial, in JAMA, vol. 291, n. 16, 2004, pp. 1963–71, DOI:10.1001/jama.291.16.1963, PMID 15113814.
* Gheorghiade M, Niazi I, Ouyang J, etal, Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial, in Circulation, vol. 107, n. 21, 2003, pp. 2690–6, DOI:10.1161/01.CIR.0000070422.41439.04, PMID 12742979.
K. Kondo, H. Ogawa, H. Yamashita, H. Miyamoto, M. Tanaka, K. Nakaya, K. Kitano, Y. Yamamura, S. Nakamura, T. Onogawa, T. Mori e M. Tominaga, 7-Cloro-5-idrossi-1-[2-metil-4-(2-metilbenzoilamino)benzoil]-2,3,4,5-tetraidro-1H-1-benzazepina (OPC-41061): A potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist, in Bioorganic & Medicinal Chemistry, vol. 7, n. 8, 1999, p. 1743, DOI:10.1016/S0968-0896(99)00101-7.

europa.eu

ema.europa.eu

EMA website, su ema.europa.eu. URL consultato il 6 novembre 2015.
Autorizzazione EMA per tolvaptan nella ADPKD (PDF), su ema.europa.eu. URL consultato l'8 novembre 2015.

fda.gov

"U.S. Food and Drug Administration." Samsca (Tolvaptan): Drug Safety Communication. N.p., 30 Apr. 2013., su fda.gov. URL consultato il 1º giugno 2014..

medicalnewstoday.com

Otsuka Maryland Research Institute, Inc.

nejm.org

(2012) Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

nih.gov

ncbi.nlm.nih.gov

Shoaf S, Elizari M, Wang Z, etal, Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias, in J Cardiovasc Pharmacol Ther, vol. 10, n. 3, 2005, pp. 165–71, DOI:10.1177/107424840501000304, PMID 16211205.
Uemura Y, Shibata R, Takemoto K, Uchikawa T, Koyasu M, et al., Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease, in Heart Vessels, 28 Nov 2015, PMID 26615607.
Gheorghiade M, Gattis W, O'Connor C, etal, Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial, in JAMA, vol. 291, n. 16, 2004, pp. 1963–71, DOI:10.1001/jama.291.16.1963, PMID 15113814.
* Gheorghiade M, Niazi I, Ouyang J, etal, Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial, in Circulation, vol. 107, n. 21, 2003, pp. 2690–6, DOI:10.1161/01.CIR.0000070422.41439.04, PMID 12742979.

oadoi.org

Shoaf S, Elizari M, Wang Z, etal, Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias, in J Cardiovasc Pharmacol Ther, vol. 10, n. 3, 2005, pp. 165–71, DOI:10.1177/107424840501000304, PMID 16211205.
Gheorghiade M, Gattis W, O'Connor C, etal, Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial, in JAMA, vol. 291, n. 16, 2004, pp. 1963–71, DOI:10.1001/jama.291.16.1963, PMID 15113814.
* Gheorghiade M, Niazi I, Ouyang J, etal, Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial, in Circulation, vol. 107, n. 21, 2003, pp. 2690–6, DOI:10.1161/01.CIR.0000070422.41439.04, PMID 12742979.
K. Kondo, H. Ogawa, H. Yamashita, H. Miyamoto, M. Tanaka, K. Nakaya, K. Kitano, Y. Yamamura, S. Nakamura, T. Onogawa, T. Mori e M. Tominaga, 7-Cloro-5-idrossi-1-[2-metil-4-(2-metilbenzoilamino)benzoil]-2,3,4,5-tetraidro-1H-1-benzazepina (OPC-41061): A potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist, in Bioorganic & Medicinal Chemistry, vol. 7, n. 8, 1999, p. 1743, DOI:10.1016/S0968-0896(99)00101-7.